Steven Lichtman
Stock Analyst at Oppenheimer
(0.86)
# 3,601
Out of 4,829 analysts
66
Total ratings
14.29%
Success rate
-5.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $312 → $324 | $316.67 | +2.31% | 6 | May 9, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $85.05 | +23.46% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $98.22 | +37.45% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $4.81 | +149.48% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $94.79 | +16.05% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $85.81 | +9.54% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $13.75 | +372.73% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $23.45 | +147.33% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $8.83 | +24.58% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $9.55 | +25.65% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $98.73 | -11.88% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $102.87 | -33.90% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $1.02 | +243.14% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $388.08 | -25.79% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $94.64 | +10.95% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $20.27 | +640.01% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $84.45 | +0.66% | 3 | Sep 4, 2020 |
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $316.67
Upside: +2.31%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $85.05
Upside: +23.46%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $98.22
Upside: +37.45%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $4.81
Upside: +149.48%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $94.79
Upside: +16.05%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $85.81
Upside: +9.54%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $13.75
Upside: +372.73%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $23.45
Upside: +147.33%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $8.83
Upside: +24.58%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.55
Upside: +25.65%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $98.73
Upside: -11.88%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $102.87
Upside: -33.90%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $1.02
Upside: +243.14%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $388.08
Upside: -25.79%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $94.64
Upside: +10.95%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $20.27
Upside: +640.01%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $84.45
Upside: +0.66%